Equities
  • Price (USD)0.67
  • Today's Change0.00 / 0.00%
  • Shares traded38.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 16:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year CSPC Pharmaceutical Group Ltd's net income fell -3.58% from 6.09bn to 5.87bn despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 28.06% to 29.49%.
Gross margin70.59%
Net profit margin17.28%
Operating margin22.01%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in CNYView more

In 2023, CSPC Pharmaceutical Group Ltd increased its cash reserves by 31.12%, or 2.49bn. The company earned 4.18bn from its operations for a Cash Flow Margin of 13.29%. In addition the company generated 607.27m cash from investing, though they paid out 2.30bn more in financing than they received.
Cash flow per share0.1576
Price/Cash flow per share32.62
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in CNYView more

CSPC Pharmaceutical Group Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)2.18%
Div growth rate (5 year)25.33%
Payout ratio (TTM)63.73%
EPS growth(5 years)13.99
EPS (TTM) vs
TTM 1 year ago
-15.24
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.